The company’s ultra-sensitive biomarker technology supports milestone achievement in establishing a method for clinicians to identify and interpret elevated values of sNfL in children...
Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics (dosing) and safety profile of nintedanib in children and adolescents...
